ACE and metabolic dysfunction-associated steatotic liver disease: In addition, the patients with overt NAFLD had higher rates of hypertension, hyperlipidemia, CKD, angiotensin converting enzyme inhibitor and angiotensin II receptor blocker treatment, and stages 3 and 4 of CKD classes, and higher diastolic blood pressure (DBP), BMI, waist circumference, TGs, creatinine, and FLI than the normal subjects and those with grade 1 NAFLD.